Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.52 |
| ▸ | THRB | P10828 | 5/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.45 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5236967 | 0.84 | TGFBR1 (0.55) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL4833999 | 0.84 | ADORA3 (0.50) | — | |
| SCHEMBL3940756 | 0.82 | THRB (0.56) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL2522815 | 0.80 | CSNK1D (0.44) | — | |
| SCHEMBL5239148 | 0.78 | TGFBR1 (0.65) | TGFBR1THRBMAPK14 | |
| SCHEMBL4820593 | 0.77 | TGFBR1 (0.54) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL14108193 | 0.77 | THRB (0.61) | TGFBR1THRBMAPK14TGFBR2MAP3K20 | |
| SCHEMBL5235790 | 0.76 | TGFBR1 (0.56) | TGFBR1THRBMAPK14 | |
| SCHEMBL18115024 | 0.74 | CSNK1D (0.46) | TGFBR1THRB | |
| SCHEMBL5235585 | 0.74 | EGFR (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511065-B2 | Mixed lineage kinase modulators | ELI LILLY AND COMPANY (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| EP-1567528-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048383-A1 | MIXED LINEAGE KINASE MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113977-A1 | Mixed Lineage Kinase Modulators | MYLK2, CSNK1G2, CSNK1A1 | TGFBR1 691/4885THRB 528/4885MAPK14 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.